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ABSTRACT Insulin-like growth factor (IGF)-binding pro-
tein 1 (IGFBP-1) contains an Arg-Gly-Asp (RGD) integrin
recognition sequence. In vitro mutagenesis was used to alter this
RGD sequence to Trp-Gly-Asp (WGD). Migration of Chinese
hamster ovary (CHO) cells expressing the wild-type protein
was more than 3-fold greater in 48 hr compared with ceUs
expressing the WGD mutant form of IGFBP-1. Similarly,
wild-type IGFBP-1 added to the media of control CHO cells
stimulated migration 2-fold compared with the WGD protein.
A synthetic RGD-containing peptide, when added to the me-
dium with wild-type IGFBP-1, blocked the effect of IGFBP-1
on cell migration. The addition of IGF-I to the culture medium
had no effect on the migration of cells expressing IGFBP-1 or
vector alone. Affmity chromatography of 12I-labeled CHO cel
membrane proteins, using IGFBP-1 coupled to agarose, iden-
tified the a51si integrin (fibronectin receptor) as the only cel
surface molecule capable of binding IGFBP-1 in an RGD-
dependent manner. Furthermore, wild-type IGFBP-1, but not
theWGD mutant form, could be coprecipitated fromCHO cells
with an antibody directed against the as integrin subunit.
These studies demonstrate that IGFBP-1 stimulates CHO cell
nmgration and binds to the a4s31 integrin receptor, both by an
RGD-dependent mechanism. The effect of IGFBP-1 on migra-
tion is independent of IGF-I and is probably mediated through
the a43.B integrin.
The insulin-like growth factor (IGF)-binding proteins
(IGFBPs) are a family of homologous but distinct proteins
that specifically bind IGF-I and IGF-II with high affinity and
are ubiquitous in biologic fluids, tissues, and the extracellular
matrix ofmost cell types (1). Currently six IGFBPs have been
purified, cloned, and sequenced (2, 3). The roles of these
proteins in intercellular transport, extracellular localization,
and the modulation of the actions of IGF-I and IGF-II are
areas of active study. The major focus of studies published to
date has been to examine the effects of the IGFBPs on
modifying IGF physiology. However, few direct non-IGF-
mediated effects of a purified form of IGFBP on cellular
functions have been reported. IGFBP-1 is a phosphorylated
protein of approximately 25 kDa that is expressed in greatest
amounts during fetal development. It has been reported to
potentiate (4) or inhibit (5) IGF actions, depending upon the
experimental conditions and degree of IGFBP-1 phosphory-
lation (6). IGFBP-1 contains an Arg-Gly-Asp (RGD) integrin
recognition sequence (7, 8) and has been shown to bind to cell
surfaces (9). The specific mechanism by which IGFBP-1 or
any of the other IGFBPs bind to cell surfaces has not been
previously described.
We undertook these studies after observing that trans-
fected Chinese hamster ovary (CHO) cells expressing human
The publication costs of this article were defrayed in part by page charge
payment. This article must therefore be hereby marked "advertisement"
in accordance with 18 U.S.C. §1734 solely to indicate this fact.
IGFBP-1 appeared to spread and migrate on tissue culture
plates more rapidly than CHO cells not expressing IGFBP-1.
Cell migration is known in many cell types to involve cellular
integrin receptor binding to RGD sequences in extracellular
matrix proteins (10). Since IGFBP-1 binds to cell surfaces
and contains an RGD sequence, we sought to determine
whether the increase in cell migration in cells expressing
IGFBP-1 required the presence of this integrin recognition
sequence and whether IGFBP-1 bound to a cell surface
integrin.
METHODS
Cells and Expression Vectors. ThepNUT expression vector
is a PUC-18-derived plasmid (11) (provided by Richard
Palmiter, University of Washington) containing a dihydrofo-
late reductase gene (12) driven by a simian virus 40 promoter
and a mouse metallothionein promoter (13) driving expres-
sion of a human growth hormone gene. An IGFBP-1 expres-
sion vector was constructed (6) by removing the growth
hormone gene and ligating in its place a cDNA encoding
human IGFBP-1. Polymerase chain reaction (PCR) was used
to mutate the IGFBP-1 coding sequence at the RGD site by
using a mutagenic primer which was complementary to the
IGFBP-1 cDNA and which encoded an Arg-to-Trp (R-to-W)
substitution at amino acid 221. The wild-type IGFBP-1 cDNA
was used as template. The PCR product was completely
sequenced and ligated into pNUT downstream from the
metallothionein promoter to construct an expression vector
for [Trp221]IGFBP-1. A control plasmid was constructed by
removing the growth hormone gene from pNUT and religat-
ing the remaining plasmid. This control plasmid, the IGFBP-1
construct, and the [Trp221]IGFBP-1 mutant construct were
each transfected into CHO-Ki cells (American Type Culture
Collection) by calcium phosphate precipitation (14).
Transfected CHO-Kl cells were selected and amplified
into stable cell lines with methotrexate (50 ,uM final concen-
tration). Three cell lines were used: CHOpNUT-A, contain-
ing the pNUT expression vector alone; CHOBP1-D6, ex-
pressing IGFBP-1; and CHOWGD-A6, expressing the RGD-
to-WGD mutant IGFBP-1. Radioimmunoassay (RIA) (15) of
the conditioned medium obtained from confluent monolayers
showed that the CHOBP1-D6 cells secreted approximately 8
,ug ofIGFBP-1 per ml in 48 hr. By ligand blot analysis (16) and
scanning laser densitometry, the CHOWGD-A6 cells se-
creted approximately 4 ug of [Trp221]IGFBP-1 per ml in 48 hr
as estimated by comparison with wild-type IGFBP-1 stan-
dards. To determine IGF mRNA abundance, total cellular
RNA was prepared (17) from the transfected CHO cell lines
and was subjected to Northern blot analysis (18), using rat
Abbreviations: IGF, insulin-like growth factor; IGFBP, IGF-binding
protein; CHO, Chinese hamster ovary.
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IGF-I (19) and IGF-II (20) probes. To quantify IGF secretion,
media (6 ml) conditioned for 24 and 48 hr by the CHOp-
NUT-A cells were lyophiized, resuspended in 1 M acetic
acid with 1251-labeled IGF-I, and fractionated by a Sephadex
column (G-50) to separate hamster IGFBP from the IGF
peptides. The fractions containing free 1251-IGF-I were
pooled and then analyzed by RIA for IGF-I (21) and IGF-II
(22). This pool was also analyzed by using an IGF binding
assay (9) to determine the amount of residual IGFBP in these
fractions. A 24-kDa IGFBP (presumably hamster IGFBP-4)
that was secreted by control CHO cells was purified to
homogeneity (23) and was used in the IGF binding assay as
a standard.
Cell Wounding and Migration Assay. Cells were plated at
1.2-1.4 x 104 cells per cm2 in a-MEM and 10% dialyzed fetal
bovine serum and allowed to grow to confluency over 3 days.
Wounding was performed by using a razor blade to scrape
cells off the culture plate, leaving a denuded area and a sharp
visible demarcation line at the wound edge (24, 25). The
wounded monolayers were rinsed twice and incubated in
serum-free a-MEM with 0.01% bovine serum albumin with or
without other test substances added to the media. The plates
were inspected immediately after wounding, and the sections
of the wounds (1.0 mm in length) that were to be used for
quantitating migration were selected, marked, and num-
bered. The cells were then incubated for 48 hr, rinsed in
phosphate-buffered saline (PBS; Sigma), fixed in 100% meth-
anol, and examined and photographed under phase-contrast
microscopy. Cells migrating 125 and 175 ,um into the denuded
area were counted in sections that were 1.0 mm in length. A
calibrated eyepiece grid was used to determine distances.
The mean number of cells migrating per 1.0-mm section of
wound was calculated by averaging a mean of 10 sections
(range 5 to 25) per test substance for each experiment.
Proteins and Peptides. Test substances added to the media
during the cell migration assay included human IGFBP-1 and
[Trp221]IGFBP-1 [purified to homogeneity from CHO cell
conditioned media as previously described (26)], human
recombinant IGF-I (Bachem), and three synthetic HPLC-
purified peptides: (i) the 13 amino acids of the sequence of
IGFBP-1 from Gly-216 to Ile-228, containing the Arg-Gly-
Asp sequence in residues 221-223 as well as 5 amino acids on
each side (a gift from Andreas Sommer, Synergen, Boulder,
CO), (ii) Gly-Arg-Gly-Asp-Ser-Pro (GRGDSP), and (iii) Gly-
Arg-Gly-Glu-Ser-Pro (GRGESP) (GRGDSP and GRGESP
were gifts from David Klapper, University of North Caroli-
na). The IGF-I-binding affinities of the two forms of IGFBP-1
were determined by a previously described solution binding
assay (6).
IGFBP-1 Affinity Chromatography and Anti-Integrin Im-
munoprecipitation. IGFBP-1 affinity matrix was prepared by
linking 1.5 mg of human IGFBP-1 [purified from human
amniotic fluid (26)] to 3 ml of carbonyldiimidazole-activated
agarose (Reactigel 6X, Pierce), according to the manufactur-
er's instructions. CHOpNUT cells (~5 x 107 cells) were
dispersed with an enzyme-free dispersant (Sigma), surface
labeled for 10 min at 22°C with 1 mCi (37 MBq) of carrier-free
Na'25I (Amersham) and Iodo-Beads (Pierce) according to the
manufacturer's instructions, washed, and then lysed at 4°C
for 30 min with 100 mM n-octyl glucoside in Hepes-buffered
saline (150 mM NaCl/40 mM Hepes, pH 7.3/1 mM CaCl2/1
mM MgSO4/1 mM MnCl2/1 mM phenylmethanesulfonyl
fluoride/l mM benzamidine). The detergent-soluble lysate
(0.6 ml) was applied to a 3-ml column of the IGFBP-1 affinity
matrix, which had been preequilibrated with elution buffer
(25 mM n-octyl glucoside in Hepes-buffered saline). The
column was clamped overnight and then bound material was
eluted with elution buffer at 6 ml/hr. GRGDSP and GRGESP
peptides were added to the elution buffer as described in the
legend to Fig. 4A. Fractions (1 ml) were concentrated 25-fold
by using a Centricon-30 microconcentrator (Amicon) and
analyzed by SDS/7% polyacrylamide gel electrophoresis
with autoradiography of the dried gels. Fractions containing
labeled cell surface proteins that were eluted from the column
with GRGDSP peptide were immunoprecipitated by using
polyclonal antibodies raised against synthetic peptides con-
taining sequences from the highly conserved cytoplasmic tail
regions of the human a2, a3, a5, av, and P3i integrin subunits
(27). These antibodies recognize integrins from many spe-
cies, including hamster, and were the generous gift of Guido
Tarone (University ofTorino, Italy). Coimmunoprecipitation
of IGFBP-1 (vs. [Trp22I]IGFBP-1) with a5,f1 integrin was
performed as described in the legend for Fig. 5.
RESULTS
Migration ofCHO Cells Is Stimulated by IGFBP-1 Through
an RGD-Dependent Mechanism. Stable methotrexate-
resistant cell lines of transfected CHO cells were established
that expressed and secreted human IGFBP-1 or the
[Trp221]IGFBP-1 mutant in which the Arg-Gly-Asp sequence
was changed to Trp-Gly-Asp (WGD). Monolayers of these
cells were wounded, and the typical appearance of the
migrating cells is shown in Fig. 1. The control cells (trans-
fected with vector alone) and the cells expressing
[Trp221]IGFBP-1 demonstrated minimal movement into the
denuded area. In contrast, the cells expressing wild-type
IGFBP-1 migrated in large numbers well into the denuded
area, with many cells moving more than 125 or 175 ,um past
the wound edge (dashed arrows). Similarly, control cells
incubated with wild-type IGFBP-1 added to the serum-free
medium migrated in large numbers into the denuded area.
However, treatment of control cells with [Trp221]IGFBP-1
had no apparent effect on cell migration or morphology (not
shown in Fig. 1).
We quantitated these observations by counting the number
of cells that had migrated more than 125 and 175 Am past the
wounded edge at the end of the 48-hr migration period. Cells
migrating less than 125 am past the wound edge could have
entered the denuded area solely as a result of division of the
cells at the edge and were therefore not included in the
analysis. However, even if the cells migrating less than 125
,um were included, the results obtained were not qualitatively






FIG. 1. Morphology ofCHO cells after wounding and migration.
CHO cells transfected with the pNUT vector alone (A; control cells),
the RGD-to-WGD mutant [Trp221]IGFBP-1 (B), and wild-type
IGFBP-1 (D) were grown to confluence, wounded with a razor blade,
and allowed to migrate into the denuded area for 48 hr in serum-free
medium. In C control cells were exposed to wild-type IGFBP-1 (1.0
pug/ml) that was added to the medium during the 48-hr incubation.
The solid arrows mark the wound edges, and the dashed arrows mark
125 and 175 um of migration. Migration was quantitated by counting
the number of cells migrating beyond these distances.
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IGFBP-1 migrated >125 and >175 Am in 3-fold greater
numbers than control cells, while the migration of cells
expressing [Trp221]IGFBP-1 was indistinguishable from con-
trol. The clone of cells used in these experiments (CHOBP1-
D6) secreted approximately 2-fold more wild-type IGFBP-1
compared with the amount of [Trp221]IGFBP-1 secreted from
CHOWGD-A6 cells. However, a separate clone (CHOBP1-
E4), which secreted an amount of wild-type IGFBP-1 equiv-
alent to the amount of mutant protein secreted by the
CHOWGD-A6 cells, also migrated in 3-fold greater numbers
than the CHOWGD-A6 cells.
Since constitutive expression of IGFBP-1 increased cell
migration, we determined whether treatment with exogenous
IGFBP-1 would stimulate migration of the control cells.
Exogenous IGFBP-1, when added to the medium of control
cells, caused a concentration-dependent increase in stimula-
tion of migration, with a response that was significant at 100
ng/ml and maximal at 1 ,ug/ml and above (not shown). While
the cells expressing IGFBP-1 demonstrated a 3-fold increase
in migration compared with control cells in serum-free me-
dium, treatment of control cells with pure IGFBP-1 (1 p&g/ml)
increased their migration 2-fold (Fig. 3). In contrast to the
wild-type protein, treatment of control cells with
[Trp221]IGFBP-1 at concentrations of 1 ,ig/ml (Fig. 3) or up
to 10 ug/ml (data not shown) had no effect. The loss of effect
on cell migration by [Trp221]IGFBP-1 was not due to differ-
ence in affinity for IGF-I, since the affinities for IGF-I of the
two forms of IGFBP-1 (measured by Scatchard analysis)
were found to be indistinguishable (Ka = 1.0 x 109 M-1 at pH
= 7.0). Importantly, the effect ofwild-type IGFBP-1 could be
completely blocked by the simultaneous addition of a syn-
thetic peptide containing the RGD sequence, while the ad-
dition of the same concentration of a control peptide (GRG-
ESP) had no effect (Fig. 3). Addition of the RGD peptide to
control cells in the absence of IGFBP-1 similarly had no
effect (not shown). When cells expressing [Trp221]IGFBP-1
were treated with wild-type IGFBP-1 at 1 gg/ml, they
responded with a 1.8-fold increase in migration (not shown).
This response was indistinguishable from the response of
control cells treated with IGFBP-1 (Fig. 3).
Migration Is Independent of IGF-I. CHO cells have IGF-I
receptors (demonstrated by affinity cross-linking) and dem-
onstrate a proliferative response to IGF-I at concentrations
between 10 and 100 ng/ml (not shown). In contrast, when
migration studies were performed in the presence ofthe same
concentrations of IGF-I no effect on migration was detected
in any of the three CHO cell lines studied (not shown). We


















> 125 gum >175 ,m
FIG. 2. Migration of three transfected CHO cell lines in serum-
free medium. The cells migrating >125 ,um and >175 Am into the
denuded area per 1.0-mm wound edge were counted and the mean
(±SEM) is expressed as a percentage of control cell migration. The
control CHO cells were transfected with the pNUT vector alone, and
the cells expressing IGFBP-1 and the WGD mutant IGFBP-1










B CHO-vector + IGFBP-1
CHO-vector + IGFBP-1 + RGD peptide
E CHO-vector + IGFBP-1 + RGE peptide
CHO-vector + WGD-mutant IGFBP-1
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FIG. 3. Blocking of the response ofCHO cells to IGFBP-1 by an
RGD-containing peptide and by mutation of the RGD sequence of
IGFBP-1. Control CHO cells were wounded and allowed to migrate
in the presence of either IGFBP-1 or the RGD-to-WGD mutant
[Trp221]IGFBP-1 at 1 Ag/ml. In some plates both IGFBP-1 and either
a synthetic 13-amino acid peptide containing RGD or RGE control
peptide at 30 fiM were added simultaneously. Migration is expressed
as a percent of migration by control cells in the absence of IGFBP-1.
Peptides were dissolved in dimethyl sulfoxide (final assay concen-
tration, 0.25%), and therefore control cells for the peptide experi-
ments were treated with 0.25% dimethyl sulfoxide (which did not
affect their migration).
IGF-II; no IGF-I or IGF-II mRNA could be detected in the
cell lysates by Northern analysis, and no IGF-I or IGF-II
peptide could be detected in CHO conditioned media after
acid gel filtration. While there was some displacement of
125I-IGF in the IGF-I and IGF-II RIAs, analysis of the gel
filtration fractions revealed that they contained a small
amount (<2% of the total) of the 24-kDa form of hamster
IGFBP. This amount of purified 24-kDa hamster IGFBP,
when added to the IGF-I and IGF-II RIAs, resulted in
approximately the same ligand displacement. Therefore all of
the apparent IGF-I and IGF-II in this pool of fractions was
due to interference by the 24-kDa IGFBP in the RIA.
IGFBP-1 Binds to the osr41 Integrin by an RGD-Dependent
Mechanism. To determine whether a cell surface integrin was
capable of recognizing IGFBP-1 in an RGD-dependent fash-
ion, we followed procedures previously used to identify
fibronectin and vitronectin receptors (28). 125I-labeled sur-
face proteins were subjected to affinity chromatography
using immobilized IGFBP-1. Labeled proteins of approxi-
mately 150 and 110 kDa (unreduced) were specifically eluted
from the column by the synthetic peptide GRGDSP but not
by the control peptide GRGESP (Fig. 4A). When these
proteins were reduced, their apparent molecular masses
changed to 135 and 130 kDa (Fig. 4B). The affinity-purified
125I-labeled proteins were immunoprecipitated with anti-
integrin antibodies (Fig. 4C). The antibodies directed against
the as and f81 integrin subunits each precipitated both bands,
while the antibodies against the a2, a3, and a, subunits
precipitated neither, indicating that the cell surface complex
which bound to immobilized IGFBP-1 was the heterodimeric
a5,j3 integrin receptor. Furthermore, the anti-a5 integrin
antibody coprecipitated soluble IGFBP-1 (Fig. 5, lane 2) but
not [Trp221]IGFBP-1 (lane 3) from cell lysates, while nonim-
mune serum did not (lanes 1 and 4), providing definitive proof
that IGFBP-1 associates with the a5f31 integrin in an RGD-
dependent fashion.
DISCUSSION
Both the expression of IGFBP-1 and the treatment of non-
expressing cells with exogenous IGFBP-1 resulted in signif-
icant increases in migration of CHO cells. This effect was
dependent on the presence in IGFBP-1 of an intact RGD
Cefl Biology: Jones et al.
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FIG. 4. .JIGFBP-1 affinity chromatography. (A) CHOpNUT cells
were surface-labeled with 125I, the detergent cell lysate was applied
to a 3-ml affinity column of immobilized IGFBP-1, and retained
proteins were eluted. The first 8 ml of eluate was discarded, and
subsequent 1-ml fractions were collected and concentrated 25-fold,
and 20 , of the concentrate was subjected to SDS/7% PAGE under
nonreducing conditions. The autoradiograph of the dried gels con-
taining fractions 1-16 is shown. The arrows indicate the times at
which the GRGESP and GRGDSP peptides (1 mg/ml for 3 ml), or
EDTA (10 mM for 5 ml) were first added to the elution buffer. Two
bands, of 150 and 110 kDa, were retained by the column and were still
equilibrating with the buffer in fractions 1-4. While no effect of the
addition of the GRGESP control peptide was observed, the addition
of the GRGDSP peptide to the elution buffer caused the 150- and
110-kDa bands to elute in fractions 9 and 10. The addition ofEDTA,
which causes the 150/110-kDa proteins to be completely eluted from
the column (not shown), resulted in no further elution of the
150/110-kDa proteins, but it did cause an unidentified 46-kDa band
to be eluted in fractions 15 and 16. (B) The 125I-labeled proteins
eluting in fraction 9 have an apparent molecular mass of 150 and 110
kDa when not reduced (NR) and apparent masses of 135 and 130 kDa
after reduction with dithiothreitol (R). (C) Pooled IGFBP-1 affinity
fractions containing the 150/110-kDa 125I-labeled proteins were
immunoprecipitated with antibodies directed against the cytoplasmic
domains of the a2, av, a3, as, and 81 integrin receptor subunits. The
as and 81 antibodies successfully precipitated both bands in the
150/110-kDa complex (arrows) indicating that the 150-kDa band is
the as integrin subunit and the 110-kDa band is the P1i subunit.
sequence, since both the mutation of this sequence to WGD
([Trp221]IGFBP-1) and the addition of excess RGD peptide
abrogated the effect. Significantly, the effect on migration of
IGFBP-1 in this system was independent of IGF-I, since (i)
the WGD mutation did not affect binding affinity for IGF-I,
(ii) addition of IGF-I to the medium had no effect on
migration of control cells or of cells expressing either
IGFBP-1 or [Trp221]IGFBP-1, and (iii) no endogenous IGF-I
or IGF-II or their mRNAs could be detected. The observa-
tion of an IGF-independent effect of IGFBP-1 and the dem-
onstration of a functional significance of its RGD sequence
are both, as far as we know, novel findings.
21.5-
FIG. 5. Coprecipitation ofIGFBP-1 with as5B8 integrin. Confluent
CHOBP1-D6 cells (lanes 1 and 2) and CHOWGD-A6 cells (lanes 3
and 4) in 10-cm dishes were incubated in serum-free medium for 24
hr then lysed in 0.5 ml of 25 mM n-octyl glucoside in Hepes-buffered
saline for 60 min. The detergent-soluble lysates (150 Al) were
incubated overnight at 4°C with 1 Au of rabbit polyclonal anti-as
integrin antiserum (lanes 2 and 3) or nonimmune rabbit serum (lanes
1 and 4) and IGFBP-1 (lanes 1 and 2) or [Trp221]IGFBP-1 (lanes 3 and
4) at 1 pg/ml. The IGFBP concentration was chosen to approximate
that present in the conditioned media of these cells. The resulting
ligand-integrin-antibody complexes were precipitated with staphy-
lococcal protein A-Sepharose (Sigma) and washed three times in the
lysis buffer, and the IGFBP-1 (or [Trp221]IGFBP-1) in the precipi-
tates was determined by SDS/12.5% PAGE and ligand blotting using
125I-IGF-I (16). The autoradiograph of the ligand blot is shown. The
arrow indicates the location of the IGFBP-1, which was precipitated
by anti-as (lane 2), while the [Trp221]IGFBP-1 did not coprecipitate
(lane 3). The nonimmune control serum (lanes 1 and 4) did not
precipitate any detectable IGFBP.
The migration results strongly suggested that IGFBP-1 had
its effect on migration by directly interacting with cell surface
integrin receptors. In addition to the classic fibronectin
receptor, the a5.81 integrin, six other integrins have been
reported to recognize the RGD sequence: the a3A1, aVPi8,
auIbP3, avP3, avP5, and aVI6 integrins (8, 29). We tested the
hypothesis that IGFBP-1 was a ligand for one or more of
these integrins by applying a surface-labeled cell lysate to an
affinity column of immobilized IGFBP-1, and we determined
that the a5P1 integrin heterodimer was the only cell surface
protein that bound to the column in an RGD-dependent
manner. Confirmation that soluble IGFBP-1 associates with
the as5p integrin was provided by the specific coprecipitation
of IGFBP-1 with the a5 integrin subunit directly from cell
lysates. Significantly, the WGD mutant form of IGFBP-1 did
not coprecipitate with the a5 integrin, confirming the RGD
dependence of binding. These experiments identify a specific
cell surface molecule that recognizes an IGFBP, and they
establish IGFBP-1 as the second known ligand, after fibro-
nectin, for the a5,81 integrin.
Since both the effect of IGFBP-1 on cell migration and its
ability to associate with the a5,81 integrin depend on an intact
RGD sequence, it is likely that stimulation of migration in our
system was mediated by binding of IGFBP-1 to the a581i
integrin receptor. The mechanism by which the interaction
between IGFBP-1 and the integrin results in increased mi-
gration is unknown. Cell adhesion molecules such as inte-
grins and their ligands clearly have effects on cell migration.
In CHO cells fibronectin stimulates migration, and the pres-
ence ofthe a5p, integrin is required for cell migration to occur
(30), but overexpression of the same integrin in CHO cells
results in decreased migration (31). An explanation for these
observations that has been proposed is that, in the absence of
this integrin, adhesion to the substratum is insufficient to
allow cell traction, while excessive adhesion resulting from
overexpression of the integrin results in decreased mobility
(29). However, the adhesion of control CHO cells to wells
coated with IGFBP-1 is not different than adhesion to bovine
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unpublished observations), suggesting that the stimulation of
migration by IGFBP-1 is not due to a direct effect ofIGFBP-1
on CHO cell adhesiveness. This would suggest that binding
of IGFBP-1 to the integrin receptor results in an intracellular
signaling event, which causes an increase in cell motility.
Such signaling functions have been suggested for integrins,
and intracellular sequelae of integrin stimulation include
activation of protein tyrosine kinases (32) such as p125FAK
(33), cytoplasmic alkalinization (34), and induction of the
AP-1 transcription factor (35). Transmission of a putative
intracellular signal resulting from IGFBP-1 binding to a5B13
integrin would require not only an intact RGD sequence but
also some other region of IGFBP-1, since the 13-amino acid
RGD peptide by itself did not stimulate migration. In this
regard, IGFBP-1 is similar to fibronectin, whose ability to
activate a5,51 integrin receptors depends not only on the
presence of its RGD sequence but also on a region of the
protein approximately 170 residues removed from the RGD
site (36). Moreover, the effects of fibronectin on cell migra-
tion are also blocked by short RGD-containing peptides (37).
Finally, the existence of an RGD-containing integrin ligand
which is not adhesive but stimulates migration is not without
precedent: tenascin is a migration-stimulating molecule that
has anti-adhesive properties (38) yet binds to cells in an
RGD-dependent fashion (39).
This effect of IGFBP-1 on cell migration may have impor-
tant physiologic consequences. IGFBP-1 is highly expressed
in multiple fetal tissues (40), in decidualized endometrium
(41), and in regenerating liver (42). Concentrations of
IGFBP-1 comparable to or greater than those used in these
studies are likely to be present in the pericellular environment
of these tissues, where the asf13 integrin is also expressed.
These are tissues in which coordinated cell migration is
known to occur. Previously, biologic effects of IGFBP-1 in
these and other systems had been believed to be limited to the
modulation of the effects of the IGFs. However, to properly
interpret such results it will be necessary to consider direct
effects of IGFBP-1. These findings raise the possibility that
the other IGFBPs (in particular IGFBP-2, which also con-
tains the RGD sequence) may also bind to integrins or other
cell surface receptors.
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